HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Stocks · News reference
Reported Earlier, Alnylam Highlights AMVUTTRA Results And New RNAi Approach For High Blood Pressure
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alnylam Pharmaceuticals To Present New Clinical And Real-World Data Across Its Transthyretin-Mediated Amyloidosis And Hypertension Programs At ESC Congress 2026
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.